| scholarly article | Q13442814 |
| P2093 | author name string | Kate Bushby | |
| P2860 | cites work | A call for transparent reporting to optimize the predictive value of preclinical research | Q24289327 |
| The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development | Q28088277 | ||
| Design, power, and interpretation of studies in the standard murine model of ALS | Q28268686 | ||
| Guidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases: "translating" the translational | Q28485060 | ||
| Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings | Q30514152 | ||
| Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies | Q33991470 | ||
| RD-Connect: an integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research | Q34011881 | ||
| The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases | Q34042850 | ||
| The burden of Duchenne muscular dystrophy: an international, cross-sectional study | Q34079312 | ||
| European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene | Q34453228 | ||
| Ataluren treatment of patients with nonsense mutation dystrophinopathy | Q34561960 | ||
| Interventions for muscular dystrophy: molecular medicines entering the clinic | Q35014916 | ||
| The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations | Q35508913 | ||
| Expanding rare disease drug trials based on shared molecular etiology | Q35993017 | ||
| The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases | Q37285058 | ||
| Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on "Pre-clinical testing for Duchenne dystrophy": Washington DC, October 27th-28th 2007 and Zürich, June 30th-July 1st 2008. | Q37396962 | ||
| Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management | Q37640907 | ||
| Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care | Q37640910 | ||
| Rare-disease genetics in the era of next-generation sequencing: discovery to translation | Q38133704 | ||
| The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia | Q38406108 | ||
| Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; Report of three expert workshops: TREAT-NMD/ENMC Workshop on outcome measures, 12th–13th May 2007, Naarden, The Netherlands; TREAT-NMD Workshop on outcome measures in exper | Q57588296 | ||
| Developing standard procedures for pre-clinical efficacy studies in mouse models of spinal muscular atrophy | Q60215160 | ||
| Choosing the right clinical outcome measure: From the patient to the statistician and back | Q85110709 | ||
| P433 | issue | s2 | |
| P304 | page(s) | S83-S87 | |
| P577 | publication date | 2015-07-01 | |
| P1433 | published in | Journal of neuromuscular diseases | Q27726242 |
| P1476 | title | Looking Forward to New Therapies: A Personal Perspective on the Translational Landscape for Muscular Dystrophies | |
| P478 | volume | 2 |
| Q38795106 | Limb-girdle muscular dystrophies - international collaborations for translational research | cites work | P2860 |
Search more.